Celgene Corporation (NASDAQ:CELG) was the recipient of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 12,302,389 shares, an increase of 37.9% from the October 31st total of 8,920,850 shares. Currently, 1.6% of the shares of the company are short sold. Based on an average daily trading volume, of 7,542,396 shares, the short-interest ratio is currently 1.6 days.

Celgene (NASDAQ CELG) opened at $102.14 on Friday. Celgene has a 52-week low of $94.55 and a 52-week high of $147.17. The company has a market capitalization of $80,420.00, a PE ratio of 16.25, a PEG ratio of 0.80 and a beta of 1.79. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52.

Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The firm had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. During the same period in the previous year, the firm posted $1.58 earnings per share. The business’s revenue was up 10.2% compared to the same quarter last year. sell-side analysts predict that Celgene will post 6.67 EPS for the current fiscal year.

Several equities analysts recently weighed in on the company. Vetr upgraded Celgene from a “buy” rating to a “strong-buy” rating and set a $148.32 target price on the stock in a research report on Thursday, August 10th. UBS downgraded Celgene from a “strong-buy” rating to a “market perform” rating and set a $160.00 target price on the stock. in a research report on Thursday, October 26th. BMO Capital Markets lowered their target price on Celgene from $163.00 to $148.00 and set an “outperform” rating on the stock in a research report on Friday, October 27th. Jefferies Group reiterated a “buy” rating and set a $160.00 target price on shares of Celgene in a research report on Friday, September 15th. Finally, BTIG Research reiterated a “neutral” rating on shares of Celgene in a research report on Tuesday, September 5th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $139.57.

In related news, Director Michael D. Casey sold 9,250 shares of Celgene stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $139.03, for a total transaction of $1,286,027.50. Following the transaction, the director now directly owns 9,250 shares in the company, valued at $1,286,027.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Terrie Curran sold 1,727 shares of Celgene stock in a transaction on Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the transaction, the insider now owns 3,925 shares in the company, valued at $564,768.25. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 20,227 shares of company stock worth $2,843,956. Company insiders own 0.95% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. BlackRock Inc. increased its stake in Celgene by 5.7% during the second quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock worth $7,366,919,000 after acquiring an additional 3,084,227 shares during the last quarter. Vanguard Group Inc. increased its stake in Celgene by 3.1% during the second quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock worth $6,951,579,000 after acquiring an additional 1,610,056 shares during the last quarter. State Street Corp increased its stake in Celgene by 2.3% during the first quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock worth $4,040,668,000 after acquiring an additional 723,844 shares during the last quarter. Jennison Associates LLC increased its stake in Celgene by 11.5% during the third quarter. Jennison Associates LLC now owns 14,962,407 shares of the biopharmaceutical company’s stock worth $2,181,818,000 after acquiring an additional 1,546,673 shares during the last quarter. Finally, FMR LLC increased its stake in Celgene by 5.9% during the second quarter. FMR LLC now owns 12,594,467 shares of the biopharmaceutical company’s stock worth $1,635,643,000 after acquiring an additional 697,250 shares during the last quarter. 80.17% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Celgene Corporation (CELG) Short Interest Up 37.9% in November” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/12/02/celgene-corporation-celg-short-interest-up-37-9-in-november.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.